Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 104

1.

rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment.

Monath TP, Fast PE, Modjarrad K, Clarke DK, Martin BK, Fusco J, Nichols R, Heppner DG, Simon JK, Dubey S, Troth SP, Wolf J, Singh V, Coller BA, Robertson JS; Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG).

Vaccine X. 2019 Jan 29;1:100009. doi: 10.1016/j.jvacx.2019.100009. eCollection 2019 Apr 11.

2.

A short history of Lassa fever: the first 10-15 years after discovery.

Monath TP.

Curr Opin Virol. 2019 Jul 16;37:77-83. doi: 10.1016/j.coviro.2019.06.005. [Epub ahead of print] Review.

PMID:
31323506
3.

Bunyavirus Taxonomy: Limitations and Misconceptions Associated with the Current ICTV Criteria Used for Species Demarcation.

Blitvich BJ, Beaty BJ, Blair CD, Brault AC, Dobler G, Drebot MA, Haddow AD, Kramer LD, LaBeaud AD, Monath TP, Mossel EC, Plante K, Powers AM, Tesh RB, Turell MJ, Vasilakis N, Weaver SC.

Am J Trop Med Hyg. 2018 Jul;99(1):11-16. doi: 10.4269/ajtmh.18-0038. Epub 2018 Apr 19.

4.

Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study.

Huttner A, Agnandji ST, Combescure C, Fernandes JF, Bache EB, Kabwende L, Ndungu FM, Brosnahan J, Monath TP, Lemaître B, Grillet S, Botto M, Engler O, Portmann J, Siegrist D, Bejon P, Silvera P, Kremsner P, Siegrist CA; VEBCON; VSV-EBOVAC; VSV-EBOPLUS Consortia.

Lancet Infect Dis. 2018 Jul;18(7):738-748. doi: 10.1016/S1473-3099(18)30165-8. Epub 2018 Apr 5.

5.

Assessment of the ability of V920 recombinant vesicular stomatitis-Zaire ebolavirus vaccine to replicate in relevant arthropod cell cultures and vector species.

Bergren NA, Miller MR, Monath TP, Kading RC.

Hum Vaccin Immunother. 2018 Apr 3;14(4):994-1002. doi: 10.1080/21645515.2017.1412898. Epub 2018 Jan 3.

6.

Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemic.

Coller BG, Blue J, Das R, Dubey S, Finelli L, Gupta S, Helmond F, Grant-Klein RJ, Liu K, Simon J, Troth S, VanRheenen S, Waterbury J, Wivel A, Wolf J, Heppner DG, Kemp T, Nichols R, Monath TP.

Vaccine. 2017 Aug 16;35(35 Pt A):4465-4469. doi: 10.1016/j.vaccine.2017.05.097. Epub 2017 Jun 21.

PMID:
28647166
7.

Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial.

ElSherif MS, Brown C, MacKinnon-Cameron D, Li L, Racine T, Alimonti J, Rudge TL, Sabourin C, Silvera P, Hooper JW, Kwilas SA, Kilgore N, Badorrek C, Ramsey WJ, Heppner DG, Kemp T, Monath TP, Nowak T, McNeil SA, Langley JM, Halperin SA; Canadian Immunization Research Network.

CMAJ. 2017 Jun 19;189(24):E819-E827. doi: 10.1503/cmaj.170074.

8.

Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.

Heppner DG Jr, Kemp TL, Martin BK, Ramsey WJ, Nichols R, Dasen EJ, Link CJ, Das R, Xu ZJ, Sheldon EA, Nowak TA, Monath TP; V920-004 study team.

Lancet Infect Dis. 2017 Aug;17(8):854-866. doi: 10.1016/S1473-3099(17)30313-4. Epub 2017 Jun 9.

PMID:
28606591
9.

Responding to the threat of urban yellow fever outbreaks.

Wilder-Smith A, Monath TP.

Lancet Infect Dis. 2017 Mar;17(3):248-250. doi: 10.1016/S1473-3099(16)30588-6. Epub 2016 Dec 23. No abstract available.

10.

Epidemic arboviral diseases: priorities for research and public health.

Wilder-Smith A, Gubler DJ, Weaver SC, Monath TP, Heymann DL, Scott TW.

Lancet Infect Dis. 2017 Mar;17(3):e101-e106. doi: 10.1016/S1473-3099(16)30518-7. Epub 2016 Dec 21. Review.

PMID:
28011234
11.

Additive Protection against Congenital Cytomegalovirus Conferred by Combined Glycoprotein B/pp65 Vaccination Using a Lymphocytic Choriomeningitis Virus Vector.

Schleiss MR, Berka U, Watson E, Aistleithner M, Kiefmann B, Mangeat B, Swanson EC, Gillis PA, Hernandez-Alvarado N, Fernández-Alarcón C, Zabeli JC, Pinschewer DD, Lilja AE, Schwendinger M, Guirakhoo F, Monath TP, Orlinger KK.

Clin Vaccine Immunol. 2017 Jan 5;24(1). pii: e00300-16. doi: 10.1128/CVI.00300-16. Print 2017 Jan.

12.

Yellow Fever Remains a Potential Threat to Public Health.

Vasconcelos PF, Monath TP.

Vector Borne Zoonotic Dis. 2016 Aug;16(8):566-7. doi: 10.1089/vbz.2016.2031. Epub 2016 Jul 11.

PMID:
27400066
13.

Unique safety issues associated with virus-vectored vaccines: Potential for and theoretical consequences of recombination with wild type virus strains.

Condit RC, Williamson AL, Sheets R, Seligman SJ, Monath TP, Excler JL, Gurwith M, Bok K, Robertson JS, Kim D, Michael Hendry R, Singh V, Mac LM, Chen RT; Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG).

Vaccine. 2016 Dec 12;34(51):6610-6616. doi: 10.1016/j.vaccine.2016.04.060. Epub 2016 Jun 23. Review.

14.

Yellow fever vaccine supply: a possible solution.

Monath TP, Woodall JP, Gubler DJ, Yuill TM, Mackenzie JS, Martins RM, Reiter P, Heymann DL.

Lancet. 2016 Apr 16;387(10028):1599-600. doi: 10.1016/S0140-6736(16)30195-7. Epub 2016 Apr 14. No abstract available. Erratum in: Lancet. 2016 Apr 30;387(10030):1816.

PMID:
27116054
15.

A Recombinant Vesicular Stomatitis Virus Ebola Vaccine.

Regules JA, Beigel JH, Paolino KM, Voell J, Castellano AR, Hu Z, Muñoz P, Moon JE, Ruck RC, Bennett JW, Twomey PS, Gutiérrez RL, Remich SA, Hack HR, Wisniewski ML, Josleyn MD, Kwilas SA, Van Deusen N, Mbaya OT, Zhou Y, Stanley DA, Jing W, Smith KS, Shi M, Ledgerwood JE, Graham BS, Sullivan NJ, Jagodzinski LL, Peel SA, Alimonti JB, Hooper JW, Silvera PM, Martin BK, Monath TP, Ramsey WJ, Link CJ, Lane HC, Michael NL, Davey RT Jr, Thomas SJ; rVSVΔG-ZEBOV-GP Study Group.

N Engl J Med. 2017 Jan 26;376(4):330-341. doi: 10.1056/NEJMoa1414216. Epub 2015 Apr 1.

16.

Yellow fever.

Monath TP, Vasconcelos PF.

J Clin Virol. 2015 Mar;64:160-73. doi: 10.1016/j.jcv.2014.08.030. Epub 2014 Oct 24. Review.

PMID:
25453327
17.

Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment.

Monath TP, Seligman SJ, Robertson JS, Guy B, Hayes EB, Condit RC, Excler JL, Mac LM, Carbery B, Chen RT; Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG).

Vaccine. 2015 Jan 1;33(1):62-72. doi: 10.1016/j.vaccine.2014.10.004. Epub 2014 Oct 27. Review.

18.

In memoriam: Robert Emmons Kissling (1923–2013).

Calisher CH, Murphy FA, Monath TP.

Emerg Infect Dis. 2014 Aug;20(8):1426-7. No abstract available.

19.

Preclinical and clinical development of a YFV 17 D-based chimeric vaccine against West Nile virus.

Dayan GH, Pugachev K, Bevilacqua J, Lang J, Monath TP.

Viruses. 2013 Dec 9;5(12):3048-70. doi: 10.3390/v5123048. Review.

20.

17D Yellow Fever Virus Vaccine.

Monath TP.

Am J Trop Med Hyg. 2013 Dec;89(6):1225. doi: 10.4269/ajtmh.13-0443a. No abstract available.

Supplemental Content

Loading ...
Support Center